Metabonomics in Preclinical Pharmaceutical Discovery and Development

The Handbook of Metabonomics and Metabolomics

Volumn , Issue , 2007, Pages 241-277

  Robertson, Donald G ^a   Reily, Michael D ^a   Cantor, Glenn H ^b  

^a PFIZER INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58449097193     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044452841-4/50010-2     Document Type: Chapter

References (113)

1. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics and its role in drug development and disease diagnosis. Review 32 refs. Expert Review of Molecular Diagnostics 2004, 4(2):189-199.
2. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics: Systems biology in pharmaceutical research and development. Current Opinion in Molecular Therapeutics 2004, 6(3):265-272.
3. Nicholson J.K., et al. Metabonomics: A platform for studying drug toxicity and gene function. Review 86 refs. Nat. Rev. Drug Discov. 2000, 1(2):153-161.
4. Nicholson J.K., Lindon J.C., Holmes E. "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29(11):1181-1189.
5. Robosky L.C., et al. In vivo toxicity screening, programs using metabonomics. Combinatorial Chemistry & High Throughput Screening 2002, 5(8):651-662.
6. Shockcor J.P., E.Holmes Metabonomic applications in toxicity screening and disease diagnosis. Current Topics in Medicinal Chemistry 2002, 2(1):35-51.
7. Harrigan G.G., Brackett D.J., Boros L.G. Medicinal chemistry, metabolic profiling and drug target discovery: A role for metabolic profiling in reverse pharmacology and chemical genetics. Review 68 refs. Mini-Reviews in Medicinal Chemistry 2005, 5(1):13-20.
8. Griffin J.L., Bollard M.E. Metabonomics: Its potential as a tool in toxicology for safety assessment and data integration. Curr. Drug Metab. 2004, 5(5):389-398.
9. Nebert D.W., E.S.Vesell Advances in pharmacogenomics and individualized, drug therapy: Exciting challenges that lie ahead. Eur. J. Pharmacol. 2004, 500(1-3):267-280.
10. Valigra L. Metabolic Profiling: Meet the Latest "Omics". Drug Discov. Develop. 2004, December:39-41.
11. Robertson D.G. Metabonomics in toxicology: A review. Toxicol. Sci. 2005, 85(2):809-822.
12. Stoughton R.B., Friend S.H. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov. 2005, 4(4):345-350.
13. Baker M. In biomarkers we trust?. Nat. Biotechnol. 2005, 23(3):297-304.
14. Pognan F. Genomics, proteomics and metabonomics in toxicology: Hopefully not "fashionomics". Pharmacogenomics 2004, 5(7):879-893.
15. Bilello J.A. The agony and ecstasy of "OMIC" technologies in drug development. Curr. Mol. Med. 2005, 5(1):39-52.
16. Witkamp R.F. Genomics and systems biology-how relevant are the developments to veterinary pharmacology, toxicology and therapeutics?. J. Vet. Pharmacol., Ther. 2005, 28(3):235-245.
17. Luhe A., et al. Toxicogenomics in the pharmaceutical industry: Hollow promises or real benefit?. Mutat. Res. 2005, 575(1-2):102-115.
18. Griffin J.L., et al. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed. 2002, 15(6):375-384.
19. Griffin J.L., et al. Cellular environment of metabolites and a metabonomic study of tamoxifen in endometrial cells using gradient high resolution magic angle spinning 1H NMR spectroscopy. Biochim. Biophys. Acta 2003, 1619(2):151-158.
20. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4(7):551-561.
21. Anthony M.L., et al. 1H NMR spectroscopic studies on the reactions of haloalkylamines with bicarbonate ions: Formation of N-carbomates and 2-oxazolidones in cell culture media and blood plasma. Chem. Res. Toxicol. 1995, 8(8):1046-1053.
22. Bailey N.J., et al. Metabolomic analysis of the consequences of cadmium exposure in Silene cucubalus cell cultures via 1H NMR spectroscopy and chemometrics. Phytochemistry 2003, 62(6):851-858.
23. Hassel B., Sonnewald U., Unsgard G., Fonnum F. NMR spectroscopy of cultured astrocytes: Effects of glutamine and the gliotoxin fluorocitrate. J. Neurochem. 1994, 62:2187-2194.
24. Sugiura Y., et al. Cadmium exposure alters metabolomics of sulfur-containing amino acids rat testes. Antioxid Redox Signal 2005, 7(5-6):781-787.
25. Verhoeckx K.C., et al. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification, of biomarkers for macrophage maturation in the U937 cell line. Proteomics 2004, 4(4):1014-1028.
26. Boros L.G., Cascante M., Lee W.N. Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Discov. Today 2002, 7(6):364-372.
27. Fiehn O. Combining genomics, metabolome analysis, and biochemical modeling to understand metabolic networks. Comp. Func. Genom. 2001, 2:155-168.
28. Brown S.C., Kruppa G., Dasseux J.L. Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom. Rev. 2005, 24(2):223-231.
29. Reily M.D., Lindon J.C. NMR Spectroscopy: Principles and instrumentation. metabonomics in Toxicity Assessment 2005, 75-104. Taylor & Francis, Boca Raton, FL, USA. J.C. Lindon, D.G. Robertson, E. Holmes, J.K. Nicholson (Eds.).
30. Lindon J.C., et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9(1):1-31.
31. Lindon J.C., Nicholson J.K., Everett J.R. NMR spectroscopy of biofluids. Ann. Rep. NMR Spect. 1999, 38:1-88.
32. Fernie A.R., et al. Metabolite profiling: From diagnostics to systems biology. Nat. Rev. Mol. Cell. Biol. 2004, 5(9):763-769.
33. Harrigan G. Metabolic profiling: Pathways in drug discovery. Drug Discovery Today 2002, 7(6):351-352.
34. van der Greef J., van der Heijden R., Verheij E.R. The role of mass spectrometry in systems biology: Data processing and identification strategies in metabolomics. Advances in Mass Spectrometry 2004, 16:145-165.
35. Robertson D.G., Reily M.D., Baker J.D. Metabonomics in Preclinical Drug Development. Expert Opin Drug Metab. Toxicol. 2005, 1(3):363-376.
36. Nicholson J.K., Buckingham M.J., Sadler P.J. High resolution 1H n.m.r. studies of vertebrate blood and plasma. Biochem. J. 1983, 211(3):605-615.
37. Bales J.R., et al. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin. Chem. 1984, 30(3):426-432.
38. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48(1-2):155-171.
39. Robertson D.G., et al. Metabonomic Technology as a Tool for Rapid Throughput In Vivo Toxicity, Screening. Comprehensive Toxicology 2002, 583-610. Elsevier Science BV, Amsterdam. J.P. Vanden Heuvel, G.J. Perdew, W.B. Mattes, W.F. Greenlee (Eds.).
40. Wilson I.D., et al. High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 2005, 4(2):591-598.
41. Smith C.A., et al. METLIN: A metabolite mass spectral database. Ther. Drug Mon. 2005, 27(6):747-751.
42. Keun H.C., et al. Analytical reproducibility in (1)H NMR-based, metabonomic urinalysis. Chem. Res. Toxicol. 2002, 15(11):1380-1386.
43. Robertson D.G., et al. Metabonomics: Evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci. 2000, 57(2):326-337.
44. Reily M.D., et al. DFTMP, an NMR reagent for assessing the near-neutral pH of biological samples. J. Am Chem. Soc. 2006, in press.
45. Siegel M., et al. Evaluation of a dual electrospray ionization/atmospheric pressure chemical ionization source at low flow rates (approx. 50uL/min) for the analysis of both highly and weakly polar compounds. J. Am. Soc. Mass Spec. 1998, 9:1196-1203.
46. Syage J.A., et al. Atmospheric pressure photoionization. II. Dual source ionization. J. Chromatogr A 2004, 1050(2):137-149.
47. Jonsson P., et al. Extraction, interpretation and validation of information for comparing samples in metabolic LC/MS data sets. Analyst 2005, 130(5):701-707.
48. Williams R.E., et al. D-Serine-induced nephrotoxicity: A HPLC-TOF/MS-based metabonomics approach. Toxicology 2005, 207(2):179-190.
49. Jonsson P., et al. High-thoughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal. Chem. 2005, 77(17):5635-5642.
50. Williams R.E., et al. A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J. Pharm. Biomed. Anal. 2005, 38(3):465-471.
51. Williams R., et al. The metabonomics of aging and development in the rat: An in vestigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using 1H NMR and HPLC-TOF MS. Molec. Biosyt. 2005, 1:166-175.
52. Lindon L.C., et al. The Consortium for Metabonomic toxicology (COMET): Aims, activities and achievements. Pharmacogenomics 2005, 6(7):691-699.
53. Lindon J.C., Nicholson J.K., Wilson I.D. Directly coupled HPLC-NMR and HPLC-NMRMS in pharmaceutical research and development. J. Chromatogr. B Biomed. Sci. Appl. 2000, 748(1):233-258.
54. Robosky L.C., et al. Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 2005, 87(1):277-284.
55. Gavaghan C.L., et al. Directly coupled high-performance liquid chromatography and nuclear magnetic resonance spectroscopic with chemometric studies on metabolic variation in Sprague-Dawley rats. Anal. Biochem. 2001, 291(2):245-252.
56. Beckwith-Hall B.M., et al. NMR-based metabonomic studies on the biochemical effects of commonly used drug carrier vehicles, in the rat. Chem. Res. Toxicol. 2002, 15(9):1136-1141.
57. Vigneau-Callahan K.E., et al. Characterization of diet-dependent metabolic serotypes: Analytical and biological variability issues in rats. J. Nutr. 2001, 131(3):924S-932S.
58. Pennie, W., S. Beushausen, and D. Robertson, Applications of genomics, proteomics and metabonomics in predictive and mechanistic toxicology, in Principles and methods in Toxicology: Fifty Edition, A. W. Hayes, Editor. In Press. Taylor & Francis: Philadelphia.
59. Deprez S., et al. Optimisation of collection, storage and preparation of rat plasma for 1H NMR spectroscopic analysis in toxicology studies to determine inherent variation in biochemical profiles. J. Pharm. Biomed. Anal. 2002, 30(4):1297-1310.
60. Pears M.R., et al. High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of batten disease. J. Biol. Chem. 2005, 280(52):42508-42514.
61. Jones G.L., et al. A functional analysis of mouse models of cardiac disease through metabolic profiling. J. Biol. Chem. 2005, 280(9):7530-7539.
62. Anonymous Biological Atlas of Insulin Resistance 2006, http://www.bair.org.uk/.
63. Cloarec O., et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic, 1H NMR data sets. Anal. Chem. 2005, 77(5):1282-1289.
64. Watkins S.M., et al. Lipid metabolome-wide effects of the PPAR gamma agonist rosiglitazone. J. Lipid. Res. 2002, 43(11):1809-1817.
65. Rae C., et al. A metabolomic approach to ionotropic glutamate receptor subtype function: A nuclear magnetic resonance in vitro investigation. J. Cereb. Blood Flow Metab. 2006, 26(8):1005-1017.
66. Boros L.G., Brackett D.J., Harrigan G.G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr. Cancer Drug Targets 2003, 3(6):445-453.
67. Bollard M.E., et al. Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol. Appl. Pharmacol. 2005, 204(2):135-151.
68. Vidal M. Interactome modeling. FEBS Lett. 2005, 579(8):1834-1838.
69. Crockford D.J., et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: Application in metabonomic toxicology studies. Anal. Chem. 2006, 78(2):363-371.
70. Anthony M.L., et al. Classification of toxin-induced changes in 1H NMR spectra of urine using an artificial neural network. J. Pharm. Biomed. Anal. 1995, 13(3):205-211.
71. Holmes E., et al. Development of a model for classification of tox in-induced lesions using 1H NMR spectroscopy of urine combined with pattern reco gnition. NMR Biomed. 1998, 11(4-5):235-244.
72. Farkas D., Tannenbaum S.R. In vitro methods to study chemically-induced hepatotoxicity: A literature review. Curr. Drug Metab. 2005, 6(2):111-125.
73. Spielmann H., Liebsch M. Lessons learned from validation of in vitro toxicity test: From failure to acceptance into regulatory practice. Toxicol. In Vitro 2001, 15(4-5):585-590.
74. Lindon J.C., et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 2003, 187(3):137-146.
75. Anthony M.L., et al. Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine. Mol. Pharmacol. 1994, 46(1):199-211.
76. Gartland K.P., Bonner F.W., Nicholson J.K. Investigations into the biochemical effects of region-specific nephrotoxins. Mol. Pharmacol. 1989, 35(2):242-250.
77. Beckwith-Hall B.M., et al. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol. 1998, 11(4):260-272.
78. Kerns W., et al. Drug-induced vascular injury - a quest for biomarkers. Toxicol. Appl. Pharmacol. 2005, 203(1):62-87.
79. Robertson D.G., et al. Metabonomic assessment of vasculitis in rats. Cardiovasc. Toxicol. 2001, 1(1):7-19.
80. Slim R.M., et al. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol. Appl. Pharmacol. 2002, 183(2):108-109.
81. Connor S.C., et al. Development of a multivariate statistical model to predict peroxisome proliferation in the rat, based on urinary 1H-NMR spectral patterns. Biomarkers 2004, 9(4-5):364-385.
82. Akira K., Imachi M., Hashimoto T. Investigations into biochemical changes of genetic hypertensive rats using 1H nuclear magnetic resonance-based metabonomics. Hypertens Res. 2005, 28(5):425-430.
83. Brindle J.T., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 2002, 8(12):1439-1444.
84. Brindle J.T., et al. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003, 128(1):32-36.
85. Sabatine M.S., et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112(25):3868-3875.
86. Fan T.W., Lane A.N., Higashi R.M. The promise of metabolomics in cancer molecular therapeutics. Curr. Opin. Mol. Ther. 2004, 6(6):584-592.
87. Odunsi K., et al. Detection of epithelial overian cancer using 1H-NMR-based metabonomics. International Journal of Cancer 2005, 113(5):782-788.
88. Griffiths J.R., Stubbs M. Opportunities for studying cancer by metabolomics: Preliminary observations on tumors deficient in hypoxia-inducible factor 1. Advances in Enzyme Regulation 2003, 43:67-76.
89. Wang C., et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal. Chem. 2005, 77(13):4108-4116.
90. Yang J., et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 2004, 813(1-2):53-58.
91. Coen M., et al. Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis. Clin. Infect. Dis. 2005, 41(11):1582-1590.
92. Van Q.N., et al. The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis. Dis. Markers 2003, 19(4-5):169-183.
93. Gibbs A. Comparison of the specificity and sensitivity of traditional methods for assessment of nephrotoxicity in the rat with metabonomic and proteomic methodologies. Journal of Applied Toxicology 2005, 25(4):277-295.
94. MacGregor J.T. The future of regulatory toxicology: Impact of the biotechnology revolution. Toxicol. Sci. 2003, 75(2):236-248.
95. Mikov M. The metabolism of drugs by the gut flora. Eur. J. Drug Metab. Pharmacokinet 1994, 19(3):201-207.
96. Rowland I.R. Interactions of the gut microflora and the host in toxicology. Toxicol. Pathol. 1988, 16(2):147-153.
97. Rowland I.R. Factors affecting metabolic activity of the intestinal microflora. Drug Metab. Rev. 1988, 19(3-4):243-261.
98. Boxenbaum H.G., et al. Influence of gut microflora on bioavailability. Drug Metab. Rev. 1979, 9(2):259-279.
99. Phipps A.N., et al. Effect of diet on the urinary excretion of hippuric acid and other dietaryderived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity. Xenobiotica 1998, 28(5):527-537.
100. Connor S.C., et al. Effects of feeding and body weight loss on the 1H-NMR-based urine metabolic profiles of male Wistar Han rats: Implications for biomarker discovery. Biomarkers 2004, 9(2):156-179.
101. Clayton T.A., et al. An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria. Arch. Toxicol. 2003, 77(4):208-217.
102. Clayton T.A., et al. Hepatotoxin-induced hypercreatinaemia and hypercreatinuria: Their relationship to one another, to liver damage and to weakened nutritional status. Arch. Toxicol. 2004, 78(2):86-96.
103. Waterfield C.J., et al. The correlation between urinary and liver taurine levels and between pre-dose urinary taurine and liver damage. Toxicology 1993, 77(1-2):1-5.
104. Waterfield C.J., et al. Taurine, a possible urinary marker of liver damage: A study of taurine excretion in carbon tetrachloride-treated rats. Arch. Toxicol. 1991, 65(7):548-555.
105. Timbrell J.A., Waterfield C.J. Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro. Adv. Exp. Med. Biol. 1996, 403:125-134.
106. Mortishire-Smith R.J., et al. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 2004, 17(2):165-173.
107. Tannehill-Gregg S., et al. Preliminary evidence of urolithiasis with muraglitazar-related urinary bladder carcinogenesis in male rats. Toxicological Sciences 2006, 90:428. (Supplement).
108. Sanderson T., et al. Carcinogneicity studies of muraglitazar, a dual PPAR alpha and gamma agonist, in mice and rats. Toxicological Sciences 2006, 90:429. (Supplement).
109. Flint O.P., et al. Characterization of HIV protease inhibitors using large-scale metabolomics of an adipocyte cell model in vitro. Presented at the 3rd International AIDS Society Conferences on HIV Pathogenesis 2005.
110. Parker R.A., et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol. Pharmacol. 2005, 67(6):1909-1919.
111. Hertel J., et al. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J. Biol. Chem. 2004, 279(53):55147-55152.
112. Robertson D.G. Metabonomics in Preclinical Safety Evaluation: Where are We. Toxicological Sciences 2006, 90:456. (Supplement).
113. Anonymous The NIH RoadMap Initiative 2006, http://www.nihroadmap.nih.gov/initiatives.asp.